put take
near-term order pipelin remain robust upsid unlik given market
expect dd growth china rt quota/u bundl model present
long-term risk direct see margin weak recurr risk given
variou potenti issu despit recent pullback share still price deliv
ntm price-to-earnings premia vs eu med-tech respect cut
ep maintain hold pt sek
near-term surpris organ growth unlik long-term risk balanc
dd order sale cycl continu believ order
pipelin market remain robust near term support continu
demand em us installed-bas expans histor
placement nevertheless expect call organ growth
compound-annual-growth-rate believ much near-term momentum reflect share
see balanc risk long-term growth downsid risk propos us
delay final term could less disrupt current outlin
meanwhil china remain signific opportun licens total vs
instal base peer commentari suggest order class licens
pull initi howev acceler could hinder
lack qualifi staff project time tender process
margin weak recurr risk mt margin target support
improv sale mix toward softwar servic increas total
scant howev think visibl margin progress remain limit
given variou potenti issu includ sharper price pressur instal
time jefe see risk recurr margin
disappoint share fell respect post two guidanc
downgrad currenc move could also affect margin significantli either
direct exchang rate differ account declin margin
invest offer strateg option drive lt uniti commercialis
view deal opportunist elekta given need rais capit
collabor allow elekta gather higher-qu clinic evid drive
reimburs adopt mr linac though near-term impact like limit
retain hold cut ep respect reflect
fx cautiou stanc margin despit recent share price declin
ektab still trade ntm pe revenu ep cagr
averag premium vs vs histor averag
even though market posit offer similar growth vs ektab
see risk multipl contract deliveri dd sale growth
could dissip market
posit offer similar growth
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
oligopolist market high barrier entri
recent market acceler sustain near
prove credibl competitor mr-
linac mr-linac market remain nich
estim benefit increas quota
china sek sale ektab
global rt market acceler mid-teen
margin recov rapidli better execut
favour price fx environ
group organ growth dd instal
china quota tailwind drive leverag
instal delay price pressur lead
margin downgrad
rt market slow histor averag level
adopt fail ramp
reinvest
recent rt market order acceler
sustain near term given sever driver
view ektab fy guidanc emin achiev
cautiou commerci opportun
could prove disappoint market
off-set posit develop elsewher
increas quota china posit
impact still uncertain estim benefit
 sek sale ektab period
order updat mridian
market develop china
pleas see import disclosur inform page report
exhibit ektab trade ntm price-to-earnings
premia vs eu med-tech respect
exhibit valuat premium vs could dissip
market posit offer similar growth
pleas see import disclosur inform page report
order growth cer sale growth cer p/eektabeu premiumv eu medtechv equiti research
pleas see import disclosur inform page report
sale yoy yoy yoy yoy product oper income/ expens netebitda cost similar tax tax number share warrant ep ep per share sale growth growth capital-expenditure less exhibit balanc sheet
pleas see import disclosur inform page report
balanc current tangibl fix intang inc fix account short-term debt sharehold ex work oper item flow oper invest free financ flow credit debt equiti ratio debt payabl old old changeforecast sekm updat model poast result reflect fx cautiou stanc margin equiti research
compani develop tool treatment plan system radiat therapi radiosurgeri brachytherapi well
softwar system use cancer care
pt base dcf risk launch execut market volatil fx upsid risk mass adopt order acceler
china downsid risk slowdown market order intak competit pressur
pt deriv via blend approach consid pe ebitda sotp dcf methodolog risk tariff halcyon
pt ev/sal discount high-growth med-tech peer risk pace adopt clinic outcom
kit cfa certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
jame vane-tempest certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
harri sephton cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
registr non-u analyst kit cfa employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
registr non-u analyst jame vane-tempest employ jefferi intern limit non-u affili jefferi
llc registered/qualifi research analyst finra analyst may associ person jefferi
llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst harri sephton cfa employ jefferi intern limit non-u affili jefferi
llc registered/qualifi research analyst finra analyst may associ person jefferi
llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom
seek updat research appropri variou regul may prevent us asid certain industri
report publish period basi larg major report publish irregular interv appropri analyst
articl articl
jefferi group llc make market secur adr inc
pleas see import disclosur inform page report
